Kong Kaili, Qiao Xiaomei, Liu Ting, Wang Xiaoxia, Li Rui, Fang Jingai, Zhang Xiaodong
Shanxi Medicial University, Taiyuan, China.
Department of Nephrology, The First Hospital of Shanxi Medical University, Taiyuan, 030001, China.
Comb Chem High Throughput Screen. 2025;28(2):306-318. doi: 10.2174/0113862073255980231113071412.
Lupus nephritis is an autoimmune disease, and its pathogenesis involves inflammation and autophagy disorders. Studies have demonstrated that Astragalus membranaceus can effectively suppress the progression of LN, but the underlying therapeutic target is still unclear.
This study aimed to investigate the therapeutic target whereby AM ameliorates LN.
We downloaded AM and LN-related chips from the TCMSP and GEO databases, respectively. We selected the two compound targets for the subsequent analysis via WGCNA, and constructed protein interaction networks of compound targets and determined the core targets. GO, KEGG analyses were conducted on compound targets to identify enriched functional and genomic pathways. The core genes were further validated in clinical and external datasets. Molecular docking of AS with the core targets was performed using the AutoDock software, and molecular dynamics simulation was conducted for the optimal core protein ligand obtained by molecular docking by Gromacs 2020.6 software.
We obtained 10 core targets, namely IL-1β, EGF, CCND1, CASP3, STAT1, PTGS2, PPARγ, AR, CXCL10, and KDR, from the 24 compound targets identified. The results of the GO enrichment analysis mainly included cell growth regulation. The results of the KEGG enrichment analysis showed that 7 out of 23 valid targets were significantly enriched in the mitogen-activated protein kinase pathway (p < 0.01). Combined with the clinical datasets, we found that IL-1β, EGF, CCND1, CASP3, STAT1, PTGS2, and PPARγ have high diagnostic values for LN. In the validation dataset, all the core targets were significantly differentially expressed, except for EGF deletion. The molecular docking and molecular dynamics simulation results showed that AM and IL- 1β, CASP3, STAT1, and PPARγ all had binding energies < -5 kJ·mol-1 and good binding properties.
IL-1β, CASP3, STAT1, and PPARγ could be potential biomarkers and therapeutic targets in AM ameliorates LN.
狼疮性肾炎是一种自身免疫性疾病,其发病机制涉及炎症和自噬紊乱。研究表明,黄芪能有效抑制狼疮性肾炎的进展,但其潜在治疗靶点仍不明确。
本研究旨在探讨黄芪改善狼疮性肾炎的治疗靶点。
我们分别从中药系统药理学数据库和分析平台(TCMSP)以及基因表达综合数据库(GEO)下载了与黄芪和狼疮性肾炎相关的芯片。我们通过加权基因共表达网络分析(WGCNA)选择了两个化合物靶点用于后续分析,并构建了化合物靶点的蛋白质相互作用网络,确定了核心靶点。对化合物靶点进行基因本体(GO)、京都基因与基因组百科全书(KEGG)分析,以识别富集的功能和基因组途径。在临床和外部数据集中对核心基因进行进一步验证。使用AutoDock软件对黄芪与核心靶点进行分子对接,并通过Gromacs 2020.6软件对分子对接获得的最佳核心蛋白配体进行分子动力学模拟。
我们从鉴定出的24个化合物靶点中获得了10个核心靶点,即白细胞介素-1β(IL-1β)、表皮生长因子(EGF)、细胞周期蛋白D1(CCND1)、半胱天冬酶3(CASP3)、信号转导和转录激活因子1(STAT1)、前列腺素内过氧化物合酶2(PTGS2)、过氧化物酶体增殖物激活受体γ(PPARγ)、雄激素受体(AR)、CXC趋化因子配体10(CXCL10)和激酶插入结构域受体(KDR)。GO富集分析结果主要包括细胞生长调节。KEGG富集分析结果显示,23个有效靶点中有7个在丝裂原活化蛋白激酶途径中显著富集(p < 0.01)。结合临床数据集,我们发现IL-1β、EGF、CCND1、CASP3、STAT1、PTGS2和PPARγ对狼疮性肾炎具有较高的诊断价值。在验证数据集中,除EGF缺失外,所有核心靶点均有显著差异表达。分子对接和分子动力学模拟结果表明,黄芪与IL-1β、CASP3、STAT1和PPARγ的结合能均 < -5 kJ·mol-1,且具有良好的结合特性。
IL-1β、CASP3、STAT1和PPARγ可能是黄芪改善狼疮性肾炎的潜在生物标志物和治疗靶点。